Newsroom
Sorted by: Latest
-
Value Group Brings Its Integrated Global IROPS Management Model to the World Aviation Festival
LISBON, Portugal--(BUSINESS WIRE)--Value Group, a leading provider of integrated aviation disruption management solutions, returns to the World Aviation Festival as a Gold Sponsor, reinforcing its role in the evolution of airline disruption management. From 13 to 15 October at FIL in Lisbon, the event is one of the aviation industry’s leading international technology conferences and exhibitions, bringing together airlines, airports and travel technology companies worldwide. At stand 1-180, Valu...
-
U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for KERENDIA® (finerenone), which is being investigated for the treatment of adults with chronic kidney disease (CKD) without diabetes who are receiving background standard of care. Key Facts The sNDA was supported by results from the Phase III FIND-CKD trial investigating KERENDIA in adults with CKD without diabete...
-
Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, and the 15-20 National Hospital (l’Hôpital national des 15-20) in Paris today announced the publication of the results of the GS030 PIONEER trial in the prestigious medical journal The New England Journal of Medicine...
-
GenSight Biologics et l'Hôpital National des 15-20 annoncent la publication dans le NEJM des résultats de l'essai de Phase 1/2 évaluant GS030 dans la rétinopathie pigmentaire au stade avancé
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, et l’Hôpital national des 15-20 à Paris, annoncent aujourd’hui la publication des résultats de l’essai PIONEER évaluant GS030 dans la prestigieuse revue médicale The New Englan...
-
Getlink SE: Trafics Navettes du mois de septembre 2026
PARIS--(BUSINESS WIRE)--Regulatory News: Getlink SE: (Paris:GET) En septembre, LeShuttle Freight a transporté 102 014 camions, en hausse de 8% par rapport à septembre 2025. Depuis le 1er janvier, ce sont plus de 883 000 camions qui ont traversé la Manche à bord des Navettes. LeShuttle a transporté 197 717 véhicules de tourisme au mois de septembre, en hausse de 2% par rapport à septembre 2025. Plus de 1 745 000 véhicules de tourisme ont ainsi été transportés depuis le 1er janvier. Sept. 26...
-
Getlink SE: Shuttle Traffic in September 2026
PARIS--(BUSINESS WIRE)--Regulatory News: Getlink SE: (Paris:GET) In September, LeShuttle Freight carried 102,014 trucks, up 8% compared to September 2025. Since 1 January, more than 883,000 trucks have crossed the Channel on board the Shuttles. LeShuttle carried 197,717 passenger vehicles in September, up 2% compared to September 2025. More than 1,745,000 passenger vehicles have been transported since 1 January. Sept. 26 Sept. 25 Change Jan.-Sept. 2026 Jan.-Sept. 2025 Change Truck Shuttles...
-
Next 15 Group plc UK Regulatory Announcement: Half-year Financial Report
LONDON--(BUSINESS WIRE)-- 8 October 2026 Next 15 Group plc (“Next 15” or the “Group”) Results for the six months ended 31 July 2026 A more focused group of high quality businesses returning to growth: Further simplification, Track 1 in growth, margins improving and current trading in line with full year expectations. Next 15 Group plc (AIM:NFG) today announces its interim results for the six months ended 31 July 2026. Financial results for the six months to 31 July 2026 (unaudited) Six month...
-
Pzena Investment Management, LLC UK Regulatory Announcement: Form 8.3 SThree Plc
NEW YORK--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Pzena Investment Management, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries mus...
-
Pershing Square Holdings, Ltd. UK Regulatory Announcement: Transaction in Own Shares
LONDON--(BUSINESS WIRE)-- Pershing Square Holdings, Ltd. Announces Transactions in Own Shares and Weekly Summary of Transactions in Own Shares – 7 October 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 7 Oct...
-
Pershing Square Holdings, Ltd. UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Pershing Square Holdings, Ltd. Releases Regular Weekly Net Asset Value and Year-To-Date Return As Of 6 October 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) today released its regular weekly Net Asset Value (“NAV”) and performance returns on its website, https://pershingsquareholdings.com/performance/net-asset-value-and-returns/. The NAV and returns were computed as of the close of business on Tuesday, 6 October 2026. PSH NAV per share as of close of business...